Biotech in Belgium: news and updates

News and Trends 25 Aug 2022

KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever

A Belgian university spinoff has generated the biggest seed capital financing in the institution’s history. Closing with €30 million ($30 million), AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

Optics11 Life receives €5 million in funding for drug development

News and Trends 24 Aug 2022

Millions in funding and new board members for Belgian mRNA company

The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences LLC with participation from Professor Kenneth Chien, […]

August 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […]

August 5, 2022 - 3 minutesmins - By Jim Cornall

In Depth 3 Aug 2022

The biggest European biotech investments in July 2022

The mRNA firm Normax Biomed snagged Europe’s biggest private biotech investment in July 2022, with runners-up including AgomAb and Tropic Biosciences. Life sciences manufacturing companies saw a big windfall in Europe in July 2022 as the Cork-based Normax Biomed bagged around $301 million. The firm is establishing modular manufacturing facilities that could provide mRNA vaccines […]

August 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Aug 2022

Clinical hold on trial for colorectal cancer drug lifted by FDA

A clinical hold has been lifted by the US Food and Drug Administration (FDA) on a trial for a treatment for colorectal cancer after changes were made by the company responsible. Belgium-based Celyad Oncology SA is a clinical biotech company focused on finding and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. […]

August 1, 2022 - 2 minutesmins - By Liza Laws

News and Trends 19 Jul 2022

eureKARE launches synthetic biology studio network

eureKARE, a company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. In conjunction with this, eureKARE has appointed Georges Rawadi as chief of biotech studio development. eureKARE said its thematic synthetic biology studio model is a novel, flexible approach […]

July 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Jul 2022

Agomab bags $114 million in thriving regenerative medicine sector

The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […]

July 14, 2022 - 3 minutesmins - By Victor Kotsev

News and Trends 28 Jun 2022

MRM Health starts pouchitis clinical trial

MRM Health, a Belgian clinical-stage biopharmaceutical company, has received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with pouchitis. MH002 is the first consortium therapy in which key disease-driving mechanisms guide therapeutic microbial […]

June 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2022

Galapagos to acquire CellPoint and AboundBio to advance cell therapies

Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy. Galapagos said the acquisitions give it access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Galapagos said the goal […]

June 22, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 21 Jun 2022

Biotalys and Novozymes partner on biofungicide

Belgian agtech company Biotalys and Danish biotech company Novozymes have entered into a partnership to expand opportunities for Evoca, Biotalys’ first proprietary biocontrol product. Novozymes will explore additional routes for the upscaling and production of the bioactive protein of Evoca, with the option of a possible commercial collaboration for a future generation of the product. […]

June 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Jun 2022

New agreement could lead to first African-owned COVID-19 vaccine

A year after the creation of the mRNA Vaccine Technology Transfer Hub, two biotech companies – Afrigen Biologics and the Univercells Group – are set to work together. The agreement intends to pave the way for the development of the first African-owned COVID-19 vaccine. The collaboration will focus on the development of a novel mRNA […]

June 21, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 16 Jun 2022

Gimv creates new fund for life science companies

European investment company Gimv has launched its fifth investment platform with a focus on venture capital investments in innovative life sciences companies. Gimv said after growth in its existing healthcare platform, a dedicated life sciences platform will strengthen its role in the international life science venture capital ecosystem. The company added its key investment focus […]

June 16, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us